Physician profile

Matthew Mainord

Internal Medicine · Kettering, OH

NPI 1912194150

$561.14

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$202.93

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $401.06 2021-2024 Freestyle Libre 3
Novo Nordisk INC $36.07 2022-2023 Ozempic, Rybelsus
Dexcom, INC. $32.93 2022
Lilly USA, LLC $31.38 2022-2023 Mounjaro
Mannkind Corporation $25.72 2021
E.R. Squibb & Sons, L.L.C. $21.00 2022
Bayer Healthcare Pharmaceuticals INC. $12.98 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Matthew Mainord

$561.14

in general payments reported 2019-2025

Years
2021-2024
Top company
Abbott Laboratories

https://glasscript.com/doctor/446407/matthew-mainord

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.